Mr. James Lee reports

HEALWELL'S DARWEN AI PLATFORM DEMONSTRATES ONE OF THE WORLD'S FIRST EXAMPLES OF USING AI TO GENERATE REGULATORY-GRADE REAL-WORLD DATA (RWD) FOR SUPPORTING PATIENT ACCESS AND ADVANCING THE PHARMACEUTICAL INDUSTRY

Healwell AI Inc.'s Darwen AI (artificial intelligence) platform has demonstrated one of the world's first examples of using AI to generate real-world data (RWD) for supporting greater patient access, product advancement and reimbursement growth for the pharmaceutical industry. AI-driven real-world data and real-world evidence (RWE) generation capability for these types of applications is globally unique to Healwell and is expected to be an important driver for both clinical and commercial value.

On Oct. 6, 2025, Healwell in collaboration with Takeda Pharmaceutical (a top 20 global pharmaceutical company) presented new AI-generated and regulatory-grade real-world data and real-world evidence on vedolizumab dose escalation in ulcerative colitis and Crohn's disease at the prestigious United European Gastroenterology (UEG) Week in Berlin. Healwell's Darwen AI platform generated real-world data, demonstrating that vedolizumab dose escalation from every eight weeks to every four weeks improved remission outcomes, supporting label advancement and access growth. Ultimately, the real-world data generated provided evidence that demonstrated remission improvement outcomes -- an important outcome to drive improved patient outcomes in a disease area that has significant population burden. Inflammatory bowel disease affects approximately 2.39 million people in the United States and nearly 400,000 people in Canada.

"Our collaboration with Takeda demonstrates how our Darwen AI platform can unlock clinically meaningful insights from the wealth of data buried and not effectively used within electronic health records and documents," said Dr. Christopher Pettengell, chief medical officer. "By identifying patient factors that influence response, we are helping clinicians and life science partners advance more precise, effective and patient-centred care. We can see a world in which the majority of RWE will be generated by novel AI systems such as Darwen AI. This will advance the speed and accuracy with which the global pharmaceutical community can advance to improve patient outcomes."

Healwell's Darwen AI platform has been globally recognized and validated with over 40 peer-reviewed published manuscripts as a leading platform in health care artificial intelligence with regard to its unique capabilities for clinical data abstraction and real-world data and evidence generation. Healwell continues to earn global recognition for its leadership in health care AI, being named a finalist in Newsweek's inaugural AI Impact Awards 2025 for advancing validated, ethical AI that drives measurable clinical and commercial impact.

"AI is reshaping our world, and the organizations receiving this award are at the forefront of that transformation," said Jennifer H. Cunningham, editor-in-chief of Newsweek. "We are proud to spotlight the companies whose technologies and practices are pushing the boundaries of what AI can achieve -- responsibly and effectively."

About Healwell AI Inc.

Healwell is a health care artificial intelligence company focused on preventive care. Its mission is to improve health care and save lives through early identification and detection of disease. Using its own proprietary technology, the company is developing and commercializing advanced clinical decision support systems that can help health care providers detect rare and chronic diseases, improve efficiency of their practice, and ultimately help improve patient health outcomes. Healwell is executing a strategy centred on developing and acquiring technology and clinical sciences capabilities that complement the company's road map. Healwell is publicly traded on the Toronto Stock Exchange under the symbol AIDX and on the OTC (over-the-counter) exchange under the symbol HWAIF.

We seek Safe Harbor.